Cargando…
Autologous Pancreatic Islet Transplantation in Human Bone Marrow
The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781459/ https://www.ncbi.nlm.nih.gov/pubmed/23733196 http://dx.doi.org/10.2337/db13-0465 |
_version_ | 1782285423053111296 |
---|---|
author | Maffi, Paola Balzano, Gianpaolo Ponzoni, Maurilio Nano, Rita Sordi, Valeria Melzi, Raffaella Mercalli, Alessia Scavini, Marina Esposito, Antonio Peccatori, Jacopo Cantarelli, Elisa Messina, Carlo Bernardi, Massimo Del Maschio, Alessandro Staudacher, Carlo Doglioni, Claudio Ciceri, Fabio Secchi, Antonio Piemonti, Lorenzo |
author_facet | Maffi, Paola Balzano, Gianpaolo Ponzoni, Maurilio Nano, Rita Sordi, Valeria Melzi, Raffaella Mercalli, Alessia Scavini, Marina Esposito, Antonio Peccatori, Jacopo Cantarelli, Elisa Messina, Carlo Bernardi, Massimo Del Maschio, Alessandro Staudacher, Carlo Doglioni, Claudio Ciceri, Fabio Secchi, Antonio Piemonti, Lorenzo |
author_sort | Maffi, Paola |
collection | PubMed |
description | The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans. |
format | Online Article Text |
id | pubmed-3781459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-37814592014-10-01 Autologous Pancreatic Islet Transplantation in Human Bone Marrow Maffi, Paola Balzano, Gianpaolo Ponzoni, Maurilio Nano, Rita Sordi, Valeria Melzi, Raffaella Mercalli, Alessia Scavini, Marina Esposito, Antonio Peccatori, Jacopo Cantarelli, Elisa Messina, Carlo Bernardi, Massimo Del Maschio, Alessandro Staudacher, Carlo Doglioni, Claudio Ciceri, Fabio Secchi, Antonio Piemonti, Lorenzo Diabetes Original Research The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans. American Diabetes Association 2013-10 2013-09-17 /pmc/articles/PMC3781459/ /pubmed/23733196 http://dx.doi.org/10.2337/db13-0465 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Maffi, Paola Balzano, Gianpaolo Ponzoni, Maurilio Nano, Rita Sordi, Valeria Melzi, Raffaella Mercalli, Alessia Scavini, Marina Esposito, Antonio Peccatori, Jacopo Cantarelli, Elisa Messina, Carlo Bernardi, Massimo Del Maschio, Alessandro Staudacher, Carlo Doglioni, Claudio Ciceri, Fabio Secchi, Antonio Piemonti, Lorenzo Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title | Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title_full | Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title_fullStr | Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title_full_unstemmed | Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title_short | Autologous Pancreatic Islet Transplantation in Human Bone Marrow |
title_sort | autologous pancreatic islet transplantation in human bone marrow |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781459/ https://www.ncbi.nlm.nih.gov/pubmed/23733196 http://dx.doi.org/10.2337/db13-0465 |
work_keys_str_mv | AT maffipaola autologouspancreaticislettransplantationinhumanbonemarrow AT balzanogianpaolo autologouspancreaticislettransplantationinhumanbonemarrow AT ponzonimaurilio autologouspancreaticislettransplantationinhumanbonemarrow AT nanorita autologouspancreaticislettransplantationinhumanbonemarrow AT sordivaleria autologouspancreaticislettransplantationinhumanbonemarrow AT melziraffaella autologouspancreaticislettransplantationinhumanbonemarrow AT mercallialessia autologouspancreaticislettransplantationinhumanbonemarrow AT scavinimarina autologouspancreaticislettransplantationinhumanbonemarrow AT espositoantonio autologouspancreaticislettransplantationinhumanbonemarrow AT peccatorijacopo autologouspancreaticislettransplantationinhumanbonemarrow AT cantarellielisa autologouspancreaticislettransplantationinhumanbonemarrow AT messinacarlo autologouspancreaticislettransplantationinhumanbonemarrow AT bernardimassimo autologouspancreaticislettransplantationinhumanbonemarrow AT delmaschioalessandro autologouspancreaticislettransplantationinhumanbonemarrow AT staudachercarlo autologouspancreaticislettransplantationinhumanbonemarrow AT doglioniclaudio autologouspancreaticislettransplantationinhumanbonemarrow AT cicerifabio autologouspancreaticislettransplantationinhumanbonemarrow AT secchiantonio autologouspancreaticislettransplantationinhumanbonemarrow AT piemontilorenzo autologouspancreaticislettransplantationinhumanbonemarrow |